CARDIOPATCH project’s innovative developments on regenerative medicine and 3D printing technologies were presented on the 25th of May in the framework of the latest edition of the Polymers & Medical Applications event. Uzuri Urtaza, researcher of the partner Leartiker, showed the main objectives of the initiative co-funded by the Interreg Sudoe Programme through the European Regional Development Fund (ERDF) , and presented their progress in the biotechnology products that will be achieved to improve the lives of people who have suffered a myocardial infarction.
Urtaza explained the work of Leartiker researchers in CARDIOPATCH, which consists of the development of a 3D system for the patch culture and transport and the design of a rollable 3D device for the non-invasive implantation of the patch.
The event was celebrated on Leartiker’s facilities and it attracted many assistants to discuss the innovations of the health industry and discover the latest advances of European projects such as CARDIOPATCH.
The first speaker of Polymers & Medical Applications 2022 was Maria Pascual, director of the Basque Health Cluster, to offer a perspective on the future of the sector in Basque Country.
Then, Jesus Izco, from Viscofan, associated partner of CARDIOPATCH, introduced the use of collagen in medical applications. And after his intervention, Alberto Sanjuan, Cardiva’s Cardiac Vascular and Endovascular Surgery Business Director, exposed instruments and materials currently used in cardiac surgery.
Following that, it was the turn of Miguel Angel Campanero from the company A3Z, who spoke about biocompatibility and risk management, specifically in the context of design and development of medical devices.
Finally, Leartiker’s researcher Ainitze Gereka presented another innovative project, LGMed, which aims to develop state-of-the-art medical devices and the promotion of different cross-border clusters.
These kinds of regional events are essential to raise awareness of the objectives and innovations developed at CARDIOPATCH, which has the aim of creating an innovative patch as a therapeutic solution for myocardial infarction patients.
Led by Clínica Universidad de Navarra (CUN), CARDIOPATCH includes partners from Spain, France and Portugal: CIMA Universidad de Navarra, via the Foundation for Applied Medical Research, Leartiker Technology Center, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, communication agency GUK, Centre Hospitalier Universitaire de Toulouse, the University of Montpellier (UM) - Institut des Biomolécules Max Mousseron (IBMM), GenIbet Biopharmaceuticals and the Instituto de Biologia Experimental e Tecnológica.